BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 30659154)

  • 1. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
    Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma.
    Gesmundo I; Pedrolli F; Vitale N; Bertoldo A; Orlando G; Banfi D; Granato G; Kasarla R; Balzola F; Deaglio S; Cai R; Sha W; Papotti M; Ghigo E; Schally AV; Granata R
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
    Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
    PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
    Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV
    Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
    Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
    Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.